MAPT and Alzheimer disease: In this study, we aimed to evaluate the safety and pharmacokinetics (PK) of MAPTRx in patients with mild AD and explore the hypothesis that precisely targeted degradation of MAPT mRNA using an ASO would result in lowering of t-tau and phosphorylated tau (p-tau) levels in the central nervous system (CNS).